Samra Turajlić: Exploring the Next Wave of Immune Engagers in Cancer Therapy at ENA 2026
Samra Turajlić/ royalmarsden.nhs.uk

Samra Turajlić: Exploring the Next Wave of Immune Engagers in Cancer Therapy at ENA 2026

Samra Turajlić, Group Leader and Director at Cancer Research UK Manchester Institute, shared on LinkedIn:

“What can we learn from the immune responses that successfully control cancer – and how can we turn that knowledge into new therapeutics?

It was a pleasure to speak and co-chair the plenary session ‘The next wave of immune engagers in cancer therapy: beyond CD3 and beyond T cells’ at ENA 2026 symposium in Barcelona.

In my presentation, ‘Tumor evolution and immune escape under therapy,’ I discussed how studying tumor evolution and immune responses under checkpoint blockade can reveal new opportunities for therapeutic discovery.

From T-cell recognition of unconventional tumor antigens and our efforts to scale TCR-antigen discovery, to the contribution of B cells, and lymph-node responses, an important theme was the potential to learn from naturally occurring anti-tumor immunity.

Looking ahead, MANIFEST IO platform offers an opportunity to study these processes longitudinally through blood, while establishing how circulating immune readouts relate to the biology of tumors and lymph nodes.

In Manchester we have a unique opportunity to connect learning from patients (The Christie NHS Foundation Trust) to experimental models and mechanistic understanding (Cancer Research UK Manchester Institute) to maximise impact.

A big thank you to Paul Parren, Victor Moreno, Christophe Blanquart and Aditya Bardia for sharing their insights and the stimulating discussion, and to my co-chair Victoria Sanchez.

Many thanks to EORTC – European Organisation for Research and Treatment of Cancer, the National Cancer Institute (NCI) and the American Association for Cancer Research and to scientific committee chairs Elena Garralda Cabanas, Tim Greten, MD and Ryan Corcoran for bringing together a fantastic programme.

And, above all, thanks to the patients, clinical teams, collaborators and researchers whose contributions make this work possible.

Special thanks to colleagues in CandyLab who have led on the work I shared”

You may also be interested in:

Yufei Xu: Astellas Pharma’s KRAS Research Presentations at the EORTC-NCI-AACR Symposium 2026

Olena Postupalenko: Three ESMO 2026 Posters That Deserve a Closer Look

Samra Turajlić: Fully Funded MB-PhD Targets Tumour-Immune Vulnerabilities With AI